AVATROPAG 20 MG: A NOVEL THROMBOPOIETIN RECEPTOR AGONIST FOR MYELODYSPLASTIC SYNDROMES

Myelodysplastic syndromes (MDS) are a group of/constitute a group of/comprise a group of hematological disorders characterized by ineffective hematopoiesis, leading to cytopenias and an increased risk of acute myeloid leukemia. Avatropag 20 mg, a novel Tukanic 150Mg (Tucatinib) thrombopoietin receptor agonist, has emerged as a promising therapeutic